Galmed Pharmaceuticals Advances Aramchol with Improved Bioavailability and Once-Daily Dosing Benefits

Galmed Pharmaceuticals Ltd (Ticker: UNDEFINED) has made significant developments in its drug Aramchol, targeting liver diseases and gastrointestinal cancers. Recent findings from a Phase 1 pharmacokinetics study demonstrate that a single 400 mg dose of Aramchol meglumine (AM) achieves around 500% greater bioavailability compared to previous dosing methods. This improvement signals a transition to a more convenient once-daily dosage, which could greatly enhance patient adherence to treatment regimens.

Innovative Developments in Drug Formulation

The study's results are pivotal for Galmed as they support the production of a GMP clinical batch for upcoming trials. The shift to a once-daily dosage is expected to significantly improve patient compliance while also potentially halving the cost of goods associated with the drug. CEO Allen Baharaff reiterated the formulation's advantages compared to other treatment candidates for metabolic-dysfunction associated steatohepatitis (MASH), a severe fatty liver condition.

Future Steps and Clinical Evaluations

The ongoing Study AM-003 will further assess the 400 mg once-daily regimen against the former 300 mg doses of Aramchol free acid. Previous trials have shown that Aramchol effectively reduces liver fat and exhibits anti-fibrotic properties, qualifying it for more extensive clinical evaluations. Over 600 subjects, including healthy volunteers and MASH patients, have participated in Aramchol trials, laying a robust foundation for its future commercialization prospects.

Prospects Ahead for Galmed Pharmaceuticals

As Galmed Pharmaceuticals advances through these clinical stages, the enhanced formulation of Aramchol is set to play a crucial role in the company’s strategy against liver diseases. The results of the ongoing studies could not only bolster their product offering but also elevate their position in the competitive pharmaceutical landscape.